Humacyte reports immaterial SVB exposure; no material impact expected

Humacyte, Inc.

Cash balance at SVB is immaterial; investment portfolio holds no SVB securities.
Loan agreement with SVB allows up to $50M; $30M drawn, no additional draws planned.
Company believes any SVB circumstance change will not materially affect cash, financial condition, or operating plans.

item 7.01

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001818382-23-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.